P813: EFFICACY, TREATMENT ADMINISTRATION SATISFACTION AND SAFETY OF SUBCUTANEOUS RAVULIZUMAB THROUGH 1 YEAR IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO RECEIVED PRIOR INTRAVENOUS ECULIZUMAB
M. N. Yenerel,
F. Sicre de Fontbrune,
C. Piatek,
F. Sahin,
W. Füreder,
M. Ogawa,
I. Tomazos,
H. Doll,
A. Ozol-Godfrey,
J. R. Sierra,
J. Szer
Affiliations
M. N. Yenerel
1 Division of Hematology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey
F. Sicre de Fontbrune
2 Hematology and Bone Marrow Transplant Unit, Assistance Publique Hôpitaux des Paris, Saint Louis Hospital, Paris, France
C. Piatek
3 Jane Anne Nohl Division of Hematology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States of America
F. Sahin
4 Department of Hematology, Ege University Bornova, Izmir, Turkey
W. Füreder
5 Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
M. Ogawa
6 Alexion, AstraZeneca Rare Disease, Boston, MA, United States of America
I. Tomazos
6 Alexion, AstraZeneca Rare Disease, Boston, MA, United States of America
H. Doll
7 Clinical Outcomes Solutions, Folkstone, United Kingdom
A. Ozol-Godfrey
6 Alexion, AstraZeneca Rare Disease, Boston, MA, United States of America
J. R. Sierra
6 Alexion, AstraZeneca Rare Disease, Boston, MA, United States of America
J. Szer
8 Haematology at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, VIC, Australia
